{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,3]],"date-time":"2025-10-03T09:32:10Z","timestamp":1759483930707,"version":"3.32.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,12,26]]},"DOI":"10.7759\/cureus.76424","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T18:13:54Z","timestamp":1735236834000},"source":"Crossref","is-referenced-by-count":1,"title":["Infliximab Precision Dosing in Inflammatory Bowel Disease (IBD) Patients: A Review of Current Literature"],"prefix":"10.7759","author":[{"given":"Alexandros","family":"Toskas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Magdalini","family":"Manti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nikolaos","family":"Kamperidis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naila","family":"Arebi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines10040749","article-title":"Is there a best first line biological\/small molecule in IBD: are we ready for sequencing?","volume":"10","author":"Hahn GD","year":"2022","unstructured":"Hahn GD, Golovics PA, Wetwittayakhlang P, Al Khoury A, Bessissow T, Lakatos PL. Is there a best first line biological\/small molecule in IBD: are we ready for sequencing?. Biomedicines. 2022, 10:749. 10.3390\/biomedicines10040749","journal-title":"Biomedicines"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1016\/S2468-1253(24)00034-7","article-title":"A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial","volume":"9","author":"Noor NM","year":"2024","unstructured":"Noor NM, Lee JC, Bond S, et al.. A biomarker-stratified comparison of top-down versus accelerated step-up treatment strategies for patients with newly diagnosed Crohn's disease (PROFILE): a multicentre, open-label randomised controlled trial. Lancet Gastroenterol Hepatol. 2024, 9:415-27. 10.1016\/S2468-1253(24)00034-7","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1007\/s11894-023-00895-4","article-title":"Precision dosing of anti-TNF therapy in pediatric inflammatory bowel disease","volume":"25","author":"Samuels A","year":"2023","unstructured":"Samuels A, Whaley KG, Minar P. Precision dosing of anti-TNF therapy in pediatric inflammatory bowel disease. Curr Gastroenterol Rep. 2023, 25:323-32. 10.1007\/s11894-023-00895-4","journal-title":"Curr Gastroenterol Rep"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2008.88","article-title":"Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review","volume":"104","author":"Gisbert JP","year":"2009","unstructured":"Gisbert JP, Pan\u00e9s J. Loss of response and requirement of infliximab dose intensification in Crohn's disease: a review. Am J Gastroenterol. 2009, 104:760-7. 10.1038\/ajg.2008.88","journal-title":"Am J Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-009-0718-4","article-title":"Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis","volume":"65","author":"Fasanmade AA","year":"2009","unstructured":"Fasanmade AA, Adedokun OJ, Ford J, et al.. Population pharmacokinetic analysis of infliximab in patients with ulcerative colitis. Eur J Clin Pharmacol. 2009, 65:1211-28. 10.1007\/s00228-009-0718-4","journal-title":"Eur J Clin Pharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1093\/crocol\/otz026","article-title":"Elevated pretreatment plasma oncostatin M is associated with poor biochemical response to infliximab","volume":"1","author":"Minar P","year":"2019","unstructured":"Minar P, Lehn C, Tsai YT, Jackson K, Rosen MJ, Denson LA. Elevated pretreatment plasma oncostatin M is associated with poor biochemical response to infliximab. Crohn's Colitis 360. 2019, 1:otz026. 10.1093\/crocol\/otz026","journal-title":"Crohn's Colitis 360"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00228-020-02975-0","article-title":"Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience","volume":"77","author":"Dave MB","year":"2021","unstructured":"Dave MB, Dherai AJ, Desai DC, Mould DR, Ashavaid TF. Optimization of infliximab therapy in inflammatory bowel disease using a dashboard approach-an Indian experience. Eur J Clin Pharmacol. 2021, 77:55-62. 10.1007\/s00228-020-02975-0","journal-title":"Eur J Clin Pharmacol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000003587","article-title":"Optimized infliximab induction predicts better long-term clinical and biomarker outcomes compared to standard induction dosing","volume":"75","author":"Lawrence S","year":"2022","unstructured":"Lawrence S, Faytrouni F, Harris RE, et al.. Optimized infliximab induction predicts better long-term clinical and biomarker outcomes compared to standard induction dosing. J Pediatr Gastroenterol Nutr. 2022, 75:601-7. 10.1097\/MPG.0000000000003587","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2020.1856405","article-title":"Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial","volume":"56","author":"Strik AS","year":"2021","unstructured":"Strik AS, L\u00f6wenberg M, Mould DR, et al.. Efficacy of dashboard driven dosing of infliximab in inflammatory bowel disease patients; a randomized controlled trial. Scand J Gastroenterol. 2021, 56:145-54. 10.1080\/00365521.2020.1856405","journal-title":"Scand J Gastroenterol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.37765\/ajmc.2023.89447","article-title":"Real-world impact of infliximab precision-guided dosing on management of patients with IBD","volume":"29","author":"Abraham BP","year":"2023","unstructured":"Abraham BP, Ziring DA, Dervieux T, Han PA, Shim A, Battat R. Real-world impact of infliximab precision-guided dosing on management of patients with IBD. Am J Manag Care. 2023, 29:S227-35. 10.37765\/ajmc.2023.89447","journal-title":"Am J Manag Care"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjab127","article-title":"Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial","volume":"16","author":"Bossuyt P","year":"2022","unstructured":"Bossuyt P, Pouillon L, Claeys S, et al.. Ultra-proactive therapeutic drug monitoring of infliximab based on point of care testing in inflammatory bowel disease: results of a pragmatic trial. J Crohn's Colitis. 2022, 16:199-206. 10.1093\/ecco-jcc\/jjab127","journal-title":"J Crohn's Colitis"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13299","article-title":"Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice","volume":"42","author":"Buurman DJ","year":"2015","unstructured":"Buurman DJ, Maurer JM, Keizer RJ, Kosterink JG, Dijkstra G. Population pharmacokinetics of infliximab in patients with inflammatory bowel disease: potential implications for dosing in clinical practice. Aliment Pharmacol Ther. 2015, 42:529-39. 10.1111\/apt.13299","journal-title":"Aliment Pharmacol Ther"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjad009","article-title":"A model-based tool for guiding infliximab induction dosing to maximize long-term deep remission in children with inflammatory bowel diseases","volume":"17","author":"Kantasiripitak W","year":"2023","unstructured":"Kantasiripitak W, Wicha SG, Thomas D, et al.. A model-based tool for guiding infliximab induction dosing to maximize long-term deep remission in children with inflammatory bowel diseases. J Crohn's Colitis. 2023, 17:896-908. 10.1093\/ecco-jcc\/jjad009","journal-title":"J Crohn's Colitis"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izx037","article-title":"A mobile infliximab dosing calculator for therapy optimization in inflammatory bowel disease","volume":"24","author":"Piester T","year":"2018","unstructured":"Piester T, Frymoyer A, Christofferson M, Yu H, Bass D, Park KT. A mobile infliximab dosing calculator for therapy optimization in inflammatory bowel disease. Inflamm Bowel Dis. 2018, 24:227-34. 10.1093\/ibd\/izx037","journal-title":"Inflamm Bowel Dis"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2018-101024","article-title":"Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study","volume":"10","author":"Kamperidis N","year":"2019","unstructured":"Kamperidis N, Middleton P, Tyrrell T, Stasinos I, Arebi N. Impact of therapeutic drug level monitoring on outcomes of patients with Crohn's disease treated with Infliximab: real world data from a retrospective single centre cohort study. Frontline Gastroenterol. 2019, 10:330-6. 10.1136\/flgastro-2018-101024","journal-title":"Frontline Gastroenterol"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/ibd\/izy203","article-title":"Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD","volume":"25","author":"Lega S","year":"2019","unstructured":"Lega S, Phan BL, Rosenthal CJ, et al.. Proactively optimized infliximab monotherapy is as effective as combination therapy in IBD. Inflamm Bowel Dis. 2019, 25:134-41. 10.1093\/ibd\/izy203","journal-title":"Inflamm Bowel Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1097\/MPG.0000000000001302","article-title":"Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease","volume":"64","author":"Hofmekler T","year":"2017","unstructured":"Hofmekler T, Bertha M, McCracken C, et al.. Infliximab optimization based on therapeutic drug monitoring in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr. 2017, 64:580-5. 10.1097\/MPG.0000000000001302","journal-title":"J Pediatr Gastroenterol Nutr"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/diagnostics13101712","article-title":"Validation study of novel point-of-care tests for infliximab, adalimumab and c-reactive protein in capillary blood and calprotectin in faeces in an ambulatory inflammatory bowel disease care setting","volume":"13","author":"Volkers A","year":"2023","unstructured":"Volkers A, L\u00f6wenberg M, Braad M, et al.. Validation study of novel point-of-care tests for infliximab, adalimumab and c-reactive protein in capillary blood and calprotectin in faeces in an ambulatory inflammatory bowel disease care setting. Diagnostics (Basel). 2023, 13:1712. 10.3390\/diagnostics13101712","journal-title":"Diagnostics (Basel)"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1080\/17512433.2021.2028619","article-title":"Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases","volume":"14","author":"Kantasiripitak W","year":"2021","unstructured":"Kantasiripitak W, Wang Z, Spriet I, Ferrante M, Dreesen E. Recent advances in clearance monitoring of monoclonal antibodies in patients with inflammatory bowel diseases. Expert Rev Clin Pharmacol. 2021, 14:1455-66. 10.1080\/17512433.2021.2028619","journal-title":"Expert Rev Clin Pharmacol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/315735-infliximab-precision-dosing-in-inflammatory-bowel-disease-ibd-patients-a-review-of-current-literature","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T18:13:56Z","timestamp":1735236836000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/315735-infliximab-precision-dosing-in-inflammatory-bowel-disease-ibd-patients-a-review-of-current-literature"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.76424","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,12,26]]}}}